Bio-Thera Conducts Simponi Phase III Trial
Study In Psoriatic Arthritis Patients Begins For BAT2506 Golimumab Biosimilar
Executive Summary
China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.
You may also be interested in...
Alvotech’s Simponi Biosimilar Steps Into Phase III RA Study
Alvotech has marked another milestone by moving its proposed biosimilar to Simponi (golimumab) into Phase III comparison studies.
Alvotech’s Simponi Rival Begins Pharmacokinetic Study
Alvotech’s Simponi rival enters Phase I trials after a dynamic year for the company’s development and commercialization program. Meanwhile, the biosimilars developer has also expanded its Japanese collaboration with Fuji Pharma.
Alvotech Reiterates Meeting US Humira Biosimilar Launch Date
Recently public Alvotech had much to share as part of its nine-month financial report, including updates on adalimumab in the US and the process to begin biosimilar golimumab trials.